Orphan Now
Orphan Now is an Andorra-based boutique consulting firm that advises orphan drug and rare-disease biopharmaceutical companies on clinical development, regulatory affairs, market access, and commercialization, leveraging a network of 12+ senior industry partners with deep rare-disease expertise.
- Company typePrivate
- Founded-
- HeadquartersAndorra la Vella, Andorra
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Orphan Now does
Orphan Now is a specialized consulting and partnering organization that advises orphan drug and rare-disease biopharmaceutical companies across the full development-to-commercialization lifecycle. Its service offering spans strategic advisory, clinical program design for small patient populations, regulatory and marketing-authorization support (including EMA MAA submissions), go-to-market strategy, market access and pricing/reimbursement, educational and commercial execution, and end-to-end patient support program design. The firm does not develop proprietary technology products; its value proposition rests entirely on the expertise and senior-level networks of its partners.
The firm is structured as a lean core entity — ORPHAN NOW, S.L.U., incorporated in the Principality of Andorra, with 9 employees — augmented by a network of 12+ independent senior partners, most of whom are themselves founders of boutique rare-disease consultancies and have held senior leadership positions at Alexion, Novartis, Shire, AstraZeneca, Pfizer, MSD, Baxalta, BioMarin, and other tier-1 pharma organizations. Partners typically carry 25-30+ years of industry experience and have built multiple rare-disease businesses across Europe and adjacent markets.
Revenue is generated through project-based consulting and partnering engagements on a quote-dependent, professional-services basis. The go-to-market motion is enterprise field sales — direct engagement with pharmaceutical and biotech clients via the company's website, email outreach, and globally distributed partner offices — targeting a broad roster of named enterprise clients that includes Pfizer, GlaxoSmithKline, BioMarin, Jazz Pharmaceuticals, Horizon Pharma, Kyowa Kirin, Ionis, Orchard Therapeutics, and 15+ other rare-disease sponsors. The firm has also built a small strategic alliance ecosystem (Supply Chain Operations, Seventeen Pharma) to extend coverage into supply-chain and adjacent operational capabilities for its orphan drug clients.
Orphan Now firmographics
Firmographics- Name
- Orphan Now
- Legal name
- ORPHAN NOW, S.L.U.
- Website
- https://orphannow.com
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Orphan Now is an Andorra-based boutique consulting firm that advises orphan drug and rare-disease biopharmaceutical companies on clinical development, regulatory affairs, market access, and commercialization, leveraging a network of 12+ senior industry partners with deep rare-disease expertise.
- Ownership category
- akta.pro rank
Orphan Now industry classification
Industry- Product category
- Pharmaceutical Consulting Services
- NAICS
- Individual and Family Services (6241)
- SIC
- Services-Health Services (8000), Services-Social Services (8300)
- akta.pro primary industry
- Rare Disease & Special Needs Support Organizations (BPAGACAM)
- akta.pro secondary industries
- Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA), Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD), Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)
Keywords
Where Orphan Now is headquartered
LocationHeadquarters
- HQ city
- Andorra la Vella
- HQ country
- Andorra
- HQ region
- Europe
Offices2 records
Markets served
Orphan Now business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D
Revenue model
- Consulting and Advisory Services: Orphan Now generates revenue through consulting and partnering engagements with orphan drug companies. Services include strategic advisory, clinical program design, marketing authorization support, go-to-market strategy development, market access, and end-to-end patient support consulting. The company acts as a trusted advisor and partner to biotech and pharmaceutical companies developing treatments for rare diseases.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels2 records
Orphan Now product offering
Product offeringCore offering
Orphan Now is a consulting and partnering organization that guides and supports orphan drug companies in developing and commercializing therapies for patients with rare diseases. Its services span strategic advisory, clinical program design, marketing authorization support, go-to-market strategy, market access, regulatory affairs, commercial execution, and end-to-end patient support consulting, delivered through a network of 12+ independent senior rare disease experts.
Product overview
Orphan Now is a consulting and partnering organization that guides and supports orphan drug companies in their quest of developing and commercializing therapies for patients with rare diseases. It offers advisory and consulting services focused on helping orphan drug companies at designing clinical programs, obtaining marketing authorizations, creating go-to-market strategies, driving educational and commercial efforts, and providing end-to-end patient support. As a consulting firm, it does not offer distinct software products or modules; instead, it provides strategic expertise through a network of independent rare disease business leaders and experts.
Differentiator
Problem solved
Functional benefit
Products and services
- Orphan Drug Consulting and Partnering Services End-to-end advisory and consulting engagement for orphan drug companies developing and commercializing therapies for rare diseases. Services span strategic advisory, clinical program design, marketing authorization support, go-to-market strategy development, market access and reimbursement, regulatory affairs, commercial execution, and end-to-end patient support program design. Delivered by a network of 12+ independent senior rare disease experts with 25-30+ years of pharmaceutical industry experience each, for enterprise pharmaceutical and biotechnology clients.
Quantifiable outcome
- The company's tagline 'We turn NO into NOW for rare disease patients and orphan drug companies' reflects their mission to accelerate patient access to needed therapies.
Companies that use Orphan Now
Customer profileNamed customers25 records
Segments1 record
Ideal customer profiles1 record
Orphan Now technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Orphan Now partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Supply Chain OperationscoreSupply Chain Operations is listed as a strategic alliance partner of Orphan Now. They collaborate to support clients and rare disease patients by providing supply chain expertise and operational capabilities in a rapidly changing pharmaceutical landscape.
- Seventeen PharmacoreSeventeen Pharma is listed as a strategic alliance partner of Orphan Now. They share common values and objectives centered on serving patients with rare diseases, contributing to Orphan Now's open ecosystem of trusted organizations.
Scale indicators1 record
Recent moves3 records
Expansion highlights4 records
Orphan Now competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Orphan Now social profiles
Digital presenceOrphan Now financial estimates
Financial estimateRevenue estimate
Valuation estimate
Orphan Now leadership team
Management profileNumber of profiles
Profiles12 records
Orphan Now funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Orphan Now M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Orphan Now
What does Orphan Now do?
Orphan Now is a consulting and partnering organization that guides and supports orphan drug companies in developing and commercializing therapies for patients with rare diseases. Its services span strategic advisory, clinical program design, marketing authorization support, go-to-market strategy, market access, regulatory affairs, commercial execution, and end-to-end patient support consulting, delivered through a network of 12+ independent senior rare disease experts.
Is Orphan Now a public or private company?
Orphan Now is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Orphan Now founded?
Orphan Now was founded in -1. It employs 1 to 10 people.
Where is Orphan Now based?
Orphan Now is headquartered in Andorra la Vella, Andorra, in the Europe region.
How does Orphan Now make money?
One revenue line is on record: consulting and Advisory Services.
Does Orphan Now have an API?
No public API is recorded for Orphan Now.
What industry is Orphan Now in?
Orphan Now's product category is Pharmaceutical Consulting Services. Its primary akta.pro industry code is BPAGACAM, Rare Disease & Special Needs Support Organizations, with a secondary code of HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics. Its NAICS code is 6241 and its SIC code is 8000.